A consensus is emerging that pharmacological inhibition of the apelin receptor might offer beneficial effects on survival, either through direct actions on stem cell populations or indirectly through anti-angiogenesis or both, in various forms of cancer, including GBM (Mastrella et al., 2019; Read et al., 2019). Here, APLNR is linked to glioblastoma.